
A Stunning Surprise: Aducanumab Works in Trials, Heads to FDA
MAYO CLINIC VIDEO, ARTICLE, PODCAST:
In March, Biogen discontinued advanced Alzheimer’s trials for aducanumab, predicting it was not likely to produce meaningful benefits. Now, new data did demonstrate real benefits, the FDA will review a fresh analysis, and former trial patients are getting back on the drug. See what happened.